The FDA last week granted Johnson & Johnson and AbbVie's Imbruvica its...

...sixth indication for the treatment of chronic lymphocytic leukemia (CLL). The drug, already a blockbuster in the space, is now approved in combination with Roche's Rituxan in CLL patients 70 or younger who have not tried another therapy. For the treatment of CLL, Imbruvica holds preferred status for 8% of covered lives in the pharmacy benefit, growing to 29% with prior authorization and/or step therapy. The drug is classified as a specialty product for 26% of all insured lives.

SOURCE: MMIT Analytics, as of 4/22/20